MCID: CHL066
MIFTS: 56

Cholangitis

Categories: Gastrointestinal diseases, Immune diseases, Liver diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cholangitis

MalaCards integrated aliases for Cholangitis:

Name: Cholangitis 11 53 43 14 71 75 31 33
Hepatic Duct Inflammation 33
Chronic Cholangiolitis 33
Bile Duct Inflammation 33
Ascending Cholangitis 33
Acute Cholangiolitis 33
Acute Cholangitis 33
Cholangitis Nos 33
Cholangiolitis 33

Classifications:



External Ids:

Disease Ontology 11 DOID:9446
ICD9CM 34 576.1
MeSH 43 D002761
NCIt 49 C26718
SNOMED-CT 68 155831003
ICD10 31 K83.0
ICD11 33 1712178777
UMLS 71 C0008311

Summaries for Cholangitis

Disease Ontology: 11 A bile duct disease that is an inflammation of the bile duct.

MalaCards based summary: Cholangitis, also known as hepatic duct inflammation, is related to sclerosing cholangitis, neonatal and chronic cholangitis. An important gene associated with Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Synthesis of bile acids and bile salts and Neuroinflammation and glutamatergic signaling. The drugs Meropenem and Cefoperazone have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and t cells, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia: 75 Cholangitis is any inflammation of the biliary tree,... more...

Related Diseases for Cholangitis

Diseases in the Cholangitis family:

Autoimmune Cholangitis Acute Cholangitis
Chronic Cholangitis

Diseases related to Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1368)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 32.8 DCDC2 CLDN1
2 chronic cholangitis 32.5 GPT DLAT ABCB4
3 autoimmune cholangitis 32.3 DLAT CA2 ABCB4
4 ascending cholangitis 32.2 MADCAM1 GPT F2 CRP ALB ABCB4
5 suppurative cholangitis 31.9 GPT F2 DLAT CRP ALB ABCB4
6 bile duct cysts 31.9 GPT CEACAM5 ALB ABCB4 ABCB11
7 acute cholangitis 31.8 IL6 GPT F2 CRP CEACAM5 ALB
8 inflammatory bowel disease 1 31.8 TNF IL6 IL10
9 cholecystitis 31.7 GPT F2 CRP ALB ABCB4
10 cholangitis, primary sclerosing 31.6 TNF NR1H4 MADCAM1 IL6 IL10 HLA-DRB1
11 cholestasis 31.5 NR1H4 GPT F2 ALPP ABCB4 ABCB11
12 liver cirrhosis 31.5 TNF IL6 HLA-DRB1 GPT F2 ALB
13 sclerosing cholangitis 31.4 TNF NR1H4 MADCAM1 IL6 IL10 GPT
14 ulcerative colitis 31.4 TNF IL6 IL10 HLA-DRB1 CRP
15 autoimmune hepatitis 31.4 TNF IL10 HLA-DRB1 GPT F2 DLAT
16 primary biliary cholangitis 31.4 TNF NR1H4 IL6 IL10 HLA-DRB1 GPT
17 colitis 31.2 TNF MADCAM1 IL6 IL10 HLA-DRB1 CRP
18 portal hypertension 31.2 TNF NR1H4 GPT F2 ALB
19 klatskin's tumor 31.1 GPT F2 CEACAM5 ALB
20 bowel dysfunction 31.1 TNF IL6 IL10 GPT CRP CFTR
21 autoimmune disease 31.0 TNF IL6 IL10 HLA-DRB1 DLAT CRP
22 autoimmune pancreatitis 31.0 IL10 CRP CFTR CEACAM5 CA2
23 bile duct cancer 31.0 IL6 GPT CEACAM5 ALB
24 biliary atresia 31.0 NR1H4 GPT F2 ALB ABCB4 ABCB11
25 ascaris lumbricoides infection 31.0 IL10 GPT ALB
26 igg4-related disease 30.9 IL10 CRP CA2
27 echinococcosis 30.9 TNF IL6 IL10 HLA-DRB1
28 varicose veins 30.9 TNF IL6 F2
29 ileitis 30.9 TNF MADCAM1 IL6 IL10
30 pancreatitis 30.8 TNF IL6 IL10 CRP CFTR CA2
31 pericholangitis 30.8 NR1H4 GPT ABCB4 ABCB11
32 toxic shock syndrome 30.8 TNF IL6 IL10 CRP
33 obstructive jaundice 30.8 GPT F2 CRP CEACAM5 ALPP ALB
34 crohn's disease 30.7 TNF MADCAM1 IL6 IL10 CRP ALB
35 colonic benign neoplasm 30.7 TNF IL6 IL10 CEACAM5
36 human cytomegalovirus infection 30.7 TNF IL6 IL10
37 acute pancreatitis 30.7 TNF IL6 IL10 GPT CRP CFTR
38 diarrhea 30.7 TNF IL6 IL10 GPT CFTR ALB
39 cholelithiasis 30.7 NR1H4 GPT CRP ALB ABCB4
40 choledocholithiasis 30.7 GPT F2 CRP CEACAM5 ALPP ALB
41 acute kidney failure 30.6 IL6 GPT F2 ALB
42 liver disease 30.6 TNF NR1H4 IL6 GPT F2 DLAT
43 inflammatory bowel disease 30.6 TNF NR1H4 MADCAM1 IL6 IL10 HLA-DRB1
44 viral infectious disease 30.6 TNF IL6 IL10 GPT
45 alopecia 30.6 TNF IL6 HLA-DRB1 CLDN1
46 hepatitis b 30.5 TNF IL6 HLA-DRB1 GPT F2 ALB
47 acquired immunodeficiency syndrome 30.5 TNF MADCAM1 IL6 IL10 CRP ALB
48 type 1 diabetes mellitus 30.5 TNF IL6 IL10 HLA-DRB1 ALB
49 portal vein thrombosis 30.5 GPT F2 CRP ALB
50 alcoholic liver cirrhosis 30.5 TNF IL6 GPT F2 ALB

Comorbidity relations with Cholangitis via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Acute Pancreatitis
Cholecystitis Cholestasis
Deficiency Anemia Familial Atrial Fibrillation
Gallbladder Cancer Heart Disease
Hepatitis Intrahepatic Gall Duct Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Postcholecystectomy Syndrome
Primary Biliary Cholangitis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Cholangitis:



Diseases related to Cholangitis

Symptoms & Phenotypes for Cholangitis

GenomeRNAi Phenotypes related to Cholangitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ABCB11 ABCB4 ALB ALPP CA2 CEACAM5
2 no effect GR00402-S-2 10.18 ABCB11 ABCB4 ALB ALPP CA2 CEACAM5

MGI Mouse Phenotypes related to Cholangitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ABCB11 ABCB4 ALB CA2 CEACAM5 CFTR
2 liver/biliary system MP:0005370 9.97 ABCB11 ABCB4 ALB CFTR GPBAR1 IL10
3 neoplasm MP:0002006 9.91 ABCB4 ALB CEACAM5 IL10 IL6 NR1H4
4 endocrine/exocrine gland MP:0005379 9.9 ABCB4 ALB CA2 CEACAM5 CFTR F2
5 digestive/alimentary MP:0005381 9.65 ABCB4 ALB CA2 CEACAM5 CFTR F2
6 immune system MP:0005387 9.44 ABCB4 ALB CA2 CEACAM5 CFTR CRP

Drugs & Therapeutics for Cholangitis

Drugs for Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
2
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185 44187
3
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
11
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
12
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
13
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
14
Ceftriaxone Approved Phase 4 73384-59-5 5479530
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Azathioprine Approved Phase 4 446-86-6 2265
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
19
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
21 Antiprotozoal Agents Phase 4
22 Antiparasitic Agents Phase 4
23 Alkylating Agents Phase 4
24 Sulperazone Phase 4
25 Antimetabolites Phase 4
26 Gastrointestinal Agents Phase 4
27 Anti-Infective Agents Phase 4
28 Hormones Phase 4
29 Antirheumatic Agents Phase 4
30 Immunologic Factors Phase 4
31 Dermatologic Agents Phase 4
32 Anti-Inflammatory Agents Phase 4
33 Hormone Antagonists Phase 4
34 glucocorticoids Phase 4
35 Immunosuppressive Agents Phase 4
36 Calcineurin Inhibitors Phase 4
37 Cyclosporins Phase 4
38 Antifungal Agents Phase 4
39 Antitubercular Agents Phase 4
40
Methylprednisolone Acetate Phase 4 584547
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Folate Phase 4
43 Vitamins Phase 4
44 Vitamin B9 Phase 4
45 Trace Elements Phase 4
46 Vitamin B1 Phase 4
47 Vitamin B Complex Phase 4
48 Thiamin Phase 4
49 Micronutrients Phase 4
50 Antineoplastic Agents, Hormonal Phase 4

Interventional clinical trials:

(show top 50) (show all 232)
# Name Status NCT ID Phase Drugs
1 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
3 Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy Completed NCT04370145 Phase 4 Sulperazon;Teicoplanin;Meropenem Injection
4 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study Completed NCT01744847 Phase 4
5 Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy Recruiting NCT04376528 Phase 4 Cyclosporin A;Mycophenolate Mofetil
6 Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
7 Clinical Research of Reducing Medication Regimen for Ursodeoxycholic Acid in Treatment of Stable Primary Biliary Cholangitis Recruiting NCT04650243 Phase 4 ursodeoxycholic acid
8 PBC Induced Fatigue Treated With Thiamine (PIFT) - The Effect of Oral Thiamine Supplement in 4 Weeks to Patients With Primary Biliary Cholangitis (PBC) and Chronic Fatigue. A Randomised Placebo Controlled Crossover Study Recruiting NCT04893993 Phase 4 Thiamine;Placebo
9 A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome Recruiting NCT04933292 Phase 4 Methylprednisolone and Mycophenolate mofetil;Methylprednisolone and azathioprine
10 Ketofol Versus Propofol in Urgent ERCP for Acute Cholangitis: A Randomized Controlled Trial Recruiting NCT04997967 Phase 4 Ketamine/Propofol;Propofol
11 A Randomized Controlled Open-label Clinical Trial of Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1 Recruiting NCT04618575 Phase 4 Ursodeoxycholic acid combined with total glucosides of paeony;Ursodeoxycholic acid only
12 Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II:A Randomized Controlled Open-label Clinical Trial Recruiting NCT04617561 Phase 4 Ursodeoxycholic acid;Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
13 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis Terminated NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
14 A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment Terminated NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
15 Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality Terminated NCT02034279 Phase 4 Albumin
16 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
17 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
18 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
19 The Safety and Efficacy of a Short Specially Designed Fully Covered Metallic Stent in the Management of Benign Post-surgical Biliary Strictures: a Randomized-controlled Study Unknown status NCT03716232 Phase 3
20 Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
21 Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
22 A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Completed NCT03602560 Phase 3 seladelpar 5-10 mg;seladelpar 10 mg;Placebo
23 Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03872921 Phase 3 norUrsodeoxycholic Acid
24 Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy Recruiting NCT04309773 Phase 3 Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Placebo of Bezafibrate in addition to standard UDCA therapy
25 A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
26 Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study Recruiting NCT04133792 Phase 3 Simvastatin 40mg;Placebo oral tablet
27 Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis Recruiting NCT04167358 Phase 3 Linerixibat
28 ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 3 Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
29 A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis Recruiting NCT05133336 Phase 2, Phase 3 Saroglitazar Magnesium 1 mg;Saroglitazar Magnesium 2 mg;Placebo
30 A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis Recruiting NCT05450887 Phase 3 Obeticholic Acid Tablets(OCA);UDCA;Placebo
31 A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC) Recruiting NCT04950127 Phase 3 Linerixibat;Placebo
32 TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib With a 52-week Extension Phase in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness Recruiting NCT05014672 Phase 2, Phase 3 Setanaxib;Placebo
33 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis Active, not recruiting NCT03890120 Phase 3 Cilofexor;Placebo
34 Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response Active, not recruiting NCT04751188 Phase 3 Bezafibrate 200 MG Oral Tablet;Placebo;Ursodeoxycholic Acid
35 RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Active, not recruiting NCT04620733 Phase 3 Seladelpar 10 mg;Placebo;Seladelpar 5 mg
36 A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid Active, not recruiting NCT04526665 Phase 3 Elafibranor 80mg;Placebo
37 Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis Terminated NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid;Placebo
38 A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
39 Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis Unknown status NCT01688024 Phase 2 Mitomycin C;Normal saline
40 Safety and Efficacy of Probiotics in Primary Biliary Cholangitis (PBC) Patients With Poor Ursodeoxycholic Acid (UDCA) Response Unknown status NCT03521297 Phase 2 Probiotic
41 A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC Completed NCT04604652 Phase 2 HTD1801 (BUDCA)
42 A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
43 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Completed NCT01988506 Phase 2 Interleukin 2
44 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
45 Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) Completed NCT03722576 Phase 2 Vidofludimus calcium
46 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT03333928 Phase 2 HTD1801;Placebo
47 An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Completed NCT02978339 Phase 1, Phase 2 Curcumin
48 PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
49 A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC) Completed NCT04024813 Phase 2 Seladelpar;Placebo to match Seladelpar
50 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2

Search NIH Clinical Center for Cholangitis

Cochrane evidence based reviews: cholangitis

Genetic Tests for Cholangitis

Anatomical Context for Cholangitis

Organs/tissues related to Cholangitis:

MalaCards : Liver, Pancreas, T Cells, Kidney, Colon, Neutrophil, Myeloid

Publications for Cholangitis

Articles related to Cholangitis:

(show top 50) (show all 17151)
# Title Authors PMID Year
1
Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. 53 62
19094117 2009
2
Preoperative determinants of common bile duct stones during laparoscopic cholecystectomy. 53 62
17887996 2008
3
Preoperative clinical and paraclinical predictors of choledocholithiasis. 53 62
18522887 2008
4
Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. 53 62
17539998 2007
5
Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. 53 62
15258199 2004
6
[Usefulness of endoscopic cholangiography and sphincterotomy in patients with biliary lithiasis]. 53 62
15765973 2004
7
Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions. 53 62
15026266 2004
8
Autoimmune liver disease. 53 62
15703563 2003
9
Role of preoperative endoscopic retrograde cholangio pancreaticography in the management of mild to moderate acute biliary pancreatitis. 53 62
19861798 2002
10
Cysteinyl leukotrienes in the bile of patients with obstructive jaundice. 53 62
12424566 2002
11
Autoimmune cholangitis within the spectrum of autoimmune liver disease. 53 62
10827147 2000
12
Autoimmune liver disease. 53 62
17023884 2000
13
Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis. 53 62
10094942 1999
14
Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II. 53 62
9605187 1998
15
Antibodies to carbonic anhydrase in patients with immune cholangiopathies. 53 62
7768386 1995
16
Initial drainage-related prognostic factors for perihilar cholangiocarcinoma: A single-center retrospective study. 62
35898846 2023
17
A rare case of inflammatory polyp in the common bile duct with cholangitis. 62
35898824 2023
18
Percutaneous transhepatic cholangioscopy-guided lithotripsy and retrieval of vascular coils eroded into the biliary tree. 62
36439934 2023
19
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe. 62
36468575 2023
20
Gastrointestinal Emergencies in the ICU. 62
36415066 2023
21
Stone removal by percutaneous papillary balloon dilatation for cystic duct and bile duct stones after cholecystectomy and distal gastrectomy with Roux-en-Y gastrojejunostomy. 62
36324847 2023
22
Autoimmune conditions and pancreatic cancer risk in older American adults. 62
36059225 2023
23
Low phospholipids associated cholelithiasis syndrome in a young women: A rare case report. 62
36324844 2023
24
Higher Complications During the Waiting Period for Interval Cholecystectomy in Patients With Mild Biliary Pancreatitis. 62
36468890 2022
25
The utility of the CADISS® system in laparoscopic cholecystectomy for acute cholecystitis. 62
36319896 2022
26
Case report of falciform ligament abscess-The importance of early diagnosis. 62
36193268 2022
27
Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study. 62
36453007 2022
28
Caspase-10 affects the pathogenesis of primary biliary cholangitis by regulating inflammatory cell death. 62
36323068 2022
29
Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis. 62
35668014 2022
30
A Case of Successful Management of Adult-Onset Linear IgA Bullous Disease With Sulfasalazine During the COVID-19 Pandemic. 62
36468952 2022
31
Practical Guide for Radiological Diagnosis of Primary and Secondary Sclerosing Cholangitis. 62
36462808 2022
32
Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. 62
35798133 2022
33
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study. 62
36426376 2022
34
Results of Intrahepatic Cholangiocarcinoma Resections: a Single-Center Analysis. 62
34989985 2022
35
Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. 62
35838934 2022
36
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. 62
35596929 2022
37
Usefulness of hepatobiliary scintigraphy for predicting late complications in patients with choledochal cysts. 62
36125544 2022
38
Optimal timing of liver transplantation for liver cirrhosis caused by sclerosing cholangitis in a patient with Langerhans cell histiocytosis: a case report. 62
36469185 2022
39
Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. 62
36444388 2022
40
Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India. 62
36453008 2022
41
Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. 62
35771958 2022
42
Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis. 62
35347534 2022
43
Clinical feasibility of endoscopic ultrasound-guided biliary drainage for preoperative management of malignant biliary obstruction (with videos). 62
36458423 2022
44
Clinical and Endoscopic Consequences of Delay in Stent Exchange Procedures With ERCP During the Covid-19 Pandemic. 62
36044333 2022
45
Mirizzi Syndrome Type IV Successfully Treated with Peroral Single-operator Cholangioscopy-guided Electrohydraulic Lithotripsy: A Case Report with Literature Review. 62
35569988 2022
46
Comparative Study on Nosocomial Biliary Tract Infection Rate Between Biliary Stent Loaded with Radioactive 125 I Seeds and Conventional Biliary Stent in the Treatment of Distal Malignant Biliary Obstruction. 62
36468897 2022
47
Suprapapillary Needle Knife Fistulotomy Versus Conventional Precut Sphincterotomy in Difficult Biliary Cannulation: A Retrospective Comparative Study. 62
36375111 2022
48
Local application of triamcinolone acetonide-conjugated chitosan membrane to prevent benign biliary stricture. 62
35426041 2022
49
The use of the T-tube in biliary tract reconstruction during orthotopic liver transplantation: An umbrella review. 62
35843181 2022
50
Impact of the Timing of Endoscopic Retrograde Cholangiopancreatography for the Treatment of Acute Cholangitis: A Meta-analysis and Systematic Review. 62
36223305 2022

Variations for Cholangitis

Expression for Cholangitis

Search GEO for disease gene expression data for Cholangitis.

Pathways for Cholangitis

Pathways related to Cholangitis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 NR1H4 ALB ABCB4 ABCB11
2 11.96 TNF IL6 IL10 DLAT
3 11.9 IL6 CFTR ALPP ALB
4 11.77 TNF IL6 IL10 CEACAM5
5
Show member pathways
11.67 IL6 HLA-DRB1 CRP
6 11.64 TNF IL6 IL10
7 11.56 TNF IL6 IL10
8 11.55 TNF IL6 IL10
9
Show member pathways
11.52 TNF IL6 IL10
10 11.4 TNF IL6 IL10
11 11.38 TNF NR1H4 IL6
12 11.35 TNF IL6 CA2
13 11.24 F2 HLA-DRB1 IL10
14 11.18 NR1H4 ABCB4 ABCB11
15 11.15 TNF IL6 IL10
16 11.11 TNF IL6 IL10 CRP
17 10.98 TNF IL6 IL10
18 10.78 TNF IL6 CRP
19 10.71 NR1H4 ABCB4 ABCB11
20 10.59 NR1H4 ABCB4 ABCB11
21 10.39 TNF IL6 IL10 HLA-DRB1
22
Show member pathways
10.27 TNF IL6

GO Terms for Cholangitis

Cellular components related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.64 TNF HLA-DRB1 GPBAR1 CLDN1 CFTR CEACAM5
2 plasma membrane GO:0005887 9.64 TNF HLA-DRB1 GPBAR1 CLDN1 CFTR CEACAM5

Biological processes related to Cholangitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to activity GO:0014823 9.97 TNF IL6 IL10
2 negative regulation of type II interferon production GO:0032689 9.95 NR1H4 IL10 HLA-DRB1
3 acute-phase response GO:0006953 9.88 IL6 F2 CRP
4 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.85 NR1H4 HLA-DRB1 CFTR
5 negative regulation of interleukin-1 production GO:0032692 9.76 NR1H4 IL10
6 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.76 TNF IL6 IL10 F2
7 negative regulation of cytokine production involved in immune response GO:0002719 9.73 TNF IL10
8 negative regulation of lipid storage GO:0010888 9.73 TNF IL6 CRP
9 chronic inflammatory response to antigenic stimulus GO:0002439 9.62 IL10 TNF
10 liver regeneration GO:0097421 9.56 TNF IL6 IL10 CLDN1
11 cellular response to bile acid GO:1903413 9.1 NR1H4 GPBAR1 ABCB4

Molecular functions related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase-coupled transmembrane transporter activity GO:0042626 9.63 CFTR ABCB4 ABCB11
2 ABC-type transporter activity GO:0140359 9.35 CFTR ABCB4 ABCB11
3 bile acid receptor activity GO:0038181 8.92 NR1H4 GPBAR1

Sources for Cholangitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....